SUBSCRIBE
SUBSCRIBE
News   Business

Helix Biopharma Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.

December 20, 2005 | 
1 min read

Helix BioPharma Corp. (Helix; TSX, FSE: “HBP”) today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.

Alliances
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Cellectar Downsizes by 60% as it Explores Strategic Options for Cancer Drug
December 11, 2024
 · 
202 min read
 · 
BioSpace Editorial Staff
Podcast
Highlights From ASH, Lilly and Novo’s Manufacturing Boon, Momentum in Neuro, More
December 11, 2024
 · 
1 min read
 · 
Heather McKenzie
Group Of Employees Being Fired By Their Company.
Layoffs
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline
December 10, 2024
 · 
2 min read
 · 
Angela Gabriel
Correct decision chosing - confused man character standing on the crossroads and looking at signpost with three different directions - conceptual vector illustration
Depression
Relmada Considering ‘Strategic Alternatives’ After Failure of Depression Asset
December 9, 2024
 · 
1 min read
 · 
Heather McKenzie